A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs MOR 106 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms IGUANA
- Sponsors Galapagos NV
- 14 Nov 2019 Planned End Date changed from 1 Jun 2020 to 1 Mar 2020.
- 14 Nov 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Nov 2019.
- 28 Oct 2019 Primary endpoint has not been met. (Percent change in Eczema Area and Severity Index (EASI) score.), according to a Galapagos NV media release.